37.2 F
New York
Friday, January 22, 2021

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) Witnesses Bullish Momentum

Must read

American Green Inc (OTCMKTS:ERBB) Stock Gains Momentum on Amazon News

One of the more interesting operators in the cannabis space in 2020 is American Green Inc (OTCMKTS:ERBB), and this week, the company...

DSG Global Inc (OTCMKTS:DSGT) Hits Multi-Month High On Sudden Optimism

DSG Global Inc (OTCMKTS:DSGT) has been in the news over the past week or so after the company placed large orders through...

AppYea Inc (OTCMKTS:APYP) Stock Gains Momentum on High Volume

Over the past couple of weeks, many stocks in the over-the-counter market have recorded considerable gains and one of the notable ones...

‘Watershed Moment’ NaturalShrimp Inc (OTCMKTS:SHMP) Stock

Aquaculture company NaturalShrimp Inc (OTCMKTS:SHMP) has been in focus among investors in recent days after the company made a major announcement.

One of the notable movers among biotech stocks of 2020 has been Northwest Biotherapeutics, Inc (OTCMKTS:NWBO), and last week, the stock was on another of its classic runs.

Last week Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) rallied by as much as 30%, and in that sort of situation; it could be worthwhile for investors to perhaps take a closer look at the stock which now sits at $1.76.

Key Factors to Watch

Currently, the stock seems to be rising on the back of feverish speculation with regards to the data from the Phase 3 trial of its product DCVax®-L. Investors are clearly lying wait for the results. More importantly, the trading volume in the Northwest stock went up considerably last week as well.

It seems that there is speculation among investors that the company could be on the verge of actually succeeding in a field in which many other companies have failed. The product in question is meant for treating Gliobastoma, which is regarded as one of the most medicine resistant variants of cancer.

It is quite deadly as well for patients and over the years some of the biggest names from the world of biotech and pharmaceuticals industry have failed. The data from the trial will end a wait that has gone on for as long as 13 years for investors.

On the other hand, it is also important to consider the potential market size when it comes to Gliobastoma treatment. It has been suggested that the total size of the market for the treatment of the cancer variant could be as much as $1.4 billion by 2025. In addition to that, Northwest’s product has also got a lot of attention from the mainstream media this year so far and that has only raised the level of anticipation among investors.

The product clearly has potential and it could be quite worthwhile for investors to keep a keen eye on the developments around the product in the coming days.

Disclaimer: We hold no position in NWBO stock.

Latest article

Sunhydrogen Inc (OTCMKTS:HYSR) Continues to Trend Higher on High Demand

One of the sectors to have come into significant focus among investors in recent times is the hydrogen...

Artificial Intelligence Technology Solutions (OTCMKTS: AITX) Moves Up Quickly On Solid Volume

The artificial intelligence industry has grown at a remarkable pace over the past half a decade or so and over the coming...

Signal Advance Inc (OTCMKTS:SIGL) Makes a Big Move, Again.

Speculation and confusion can often lead to strange occurrences on the stock markets and that is what happened...

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...